Hepatitis Testing/Diagnosis Market Analysis and Forecast to 2031: By Diseases Type (Hepatitis B, Hepatitis C, Others Hepatitis), Technology (ELISA, RDT, PCR, INAAT, Others), End User (Hospital & Diagnostic Laboratories, Blood Banks, Others), and Region

Hepatitis Testing/Diagnosis Market Analysis and Forecast to 2031: By Diseases Type (Hepatitis B, Hepatitis C, Others Hepatitis), Technology (ELISA, RDT, PCR, INAAT, Others), End User (Hospital & Diagnostic Laboratories, Blood Banks, Others), and Region

The global hepatitis testing/diagnosis market was valued at USD 2.6 billion in 2021 and it is anticipated to reach up to USD 4.4 billion by 2031, at a CAGR of 5.5% during the forecast period.

The goal of hepatitis diagnosis is to identify the genotype of the infection that is causing the condition. The optimal course of treatment for the patient can be chosen based on the hepatitis diagnosis. In order to distinguish between different hepatitis viruses, it is crucial to make a diagnosis of the illness. Inflammation in the liver is the primary cause of hepatitis. Different forms of the hepatitis virus, including Hepatitis A, B, and C, are recognized. Blood tests are used to identify the presence of hepatitis disease. Testing bodily proteins or genetic material that is a component of the virus can also be used to identify hepatitis.

Market Trends and Drivers

Despite substantial advancements in treatment options, immunization coverage, and public awareness, hepatitis remains a serious public health concern with a high prevalence rate worldwide. The most common hepatitis forms, B and C, are associated with greater fatality rates. According to estimates, 296 million and 58 million persons, respectively, had chronic HBV and HCV infections in 2019. Compared to industrialized countries, hepatitis is more common in poor nations. Similarly, the biotechnology and biopharmaceutical industries have a significant demand for immunoassay equipment and supplies. Therefore, over the forecast period, the expansion of these industries is anticipated to boost the expansion of the hepatitis testing market. The expansion of the end-user market in these sectors has prompted numerous businesses to introduce new products and make investments in the development of cutting-edge products. Since immunoassays are used throughout the production process, from product development and manufacturing to quality control, this is regarded as a promising sign for the market's expansion.

Market Restraints and Challenges

Due to the cost of the test and the need for experienced staff, NAT is not required in developing and low-resource countries. Only 58 blood banks out of 2,550 (less than 2 percent) in India performed NAT for hepatitis diagnosis as of 2016. The fact that ELISA is the only test that is required in many developing nations, like China and India, significantly hinders the implementation of NAT. There are no laws requiring the use of NAT in India, where blood screening includes serological testing for hepatitis surface antigens. Because of this, patients who undergo hepatitis diagnostic tests are unsure about the outcomes, which limits market expansion.

Global Hepatitis Testing/Diagnosis Market Segmental Overview

The report analyses the global hepatitis testing/diagnosis market based on disease type, technology, end user, and region.

Global Hepatitis Testing/Diagnosis Market by Type

Based on the type, it is segmented into hepatitis B, hepatitis C, and other hepatitis. The hepatitis B segment dominated the hepatitis testing market in 2021. Hepatitis B is becoming more common, there are more hepatitis B diagnostic tests available, and more people are using nucleic acid tests to diagnose HBV, which is what is fueling the growth of this market segment.

Global Hepatitis Testing/Diagnosis Market by Technology

Based on the technology, it is segmented into enzyme-linked immunosorbent assay, rapid diagnostic tests, polymerase chain reaction, isothermal nucleic acid amplification technology, and other technologies. The ELISA segment to witness the highest market share during the projection period. The substantial proportion of this market is primarily due to the widespread use of this test to identify hepatitis in clinical settings.

Global Hepatitis Testing/Diagnosis Market by End User

Based on the end user, it is segmented into hospital & diagnostic laboratories, blood banks, and other end users. The hospital & diagnostic laboratories segment is anticipated to witness the fastest growth during the forecast period. The key factors such as high burden of hepatitis coupled with increasing blood transfusion and donations are boosting the growth of the segment in the market.

Geographical Analysis of the Global Hepatitis Testing/Diagnosis Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America was the largest regional market for hepatitis testing/diagnosis market in 2021. The rapid growth and significant share of this region can be linked to the US's expanded hepatitis testing research and clinical trials as well as the disease's rising prevalence.

Major Players in the Global Hepatitis Testing/Diagnosis Market

COVID-19 Impact

Due to fewer hospital visits caused by the COVID-19 outbreak, the market for hepatitis testing suffered. Healthcare systems are under a lot of stress as a result of the pandemic. To reduce the disease's spread and save money for COVID-19 sufferers, healthcare institutions and clinicians were told to avoid performing elective surgical procedures and physical exams. As a result, the testing volume at numerous clinical laboratories for hepatitis testing rapidly decreased. The American Journal of Preventive Medicine reports that hepatitis C testing has significantly decreased across the US. The study's findings, "Decreases in Hepatitis C Testing and Treatment," HCV antibody tests that were suggested by the COVID-19 Pandemic decreased by 59 percent in April 2020 before increasing to a 6 percent decline in July 2020. In contrast, the number of HCV RNA-positive tests dropped by 62% in March 2020 and 39% in July 2020.

Recent Developments

• July 2021, Bio-Rad Laboratories, Inc. partnered with Seegene, Inc. The partnership aims at collaborative development and the commercialization of infectious disease diagnostic products.
• March 2021, Abbott received FDA Emergency Use Authorization (EUA) for the Alinity m Resp-4-Plex assay.
• March 2021, F. Hoffmann-La Roche Ltd. Acquired Gen Mark Diagnostics which aimed at adding more products to Roche’s molecular diagnostics portfolio and the global distribution of products offered by Gen Mark Diagnostics.
• May 2020, Vela Diagnostics lauched an NGS-based test used in the detection of HIV-1, HCV, HBV, and CMV.

Frequently Asked QuestionsQ1. How big is the Hepatitis Testing/Diagnosis market?Ans. The global Hepatitis Testing/Diagnosis market size was USD 2.6 billion in 2021 and is anticipated to reach USD 4.4 billion in 2031, growing at a rate of 5.5% from 2022 to 2031.Q2. What is the Hepatitis Testing/Diagnosis market growth rate?Ans. The growth rate of the Hepatitis Testing/Diagnosis market is 5.5%.Q3. Which region holds a major market share for the Hepatitis Testing/Diagnosis market?Ans. North America holds a major market share of the Hepatitis Testing/Diagnosis market in 2021.Q4. Which segment accounted for the largest Hepatitis Testing/Diagnosis market share?Ans. By end user, hospital & diagnostic laboratories segment accounted for the largest Hepatitis Testing/Diagnosis market share.Q5. Who are the key players in the Hepatitis Testing/Diagnosis market?Q6. What are the factors driving the Hepatitis Testing/Diagnosis market growth?Ans. The major factors driving the growth of the market are the growing healthcare market in emerging countries.Q7. What are the key growth strategies of Hepatitis Testing/Diagnosis market players?Ans. The key growth strategies of Hepatitis Testing/Diagnosis market players are product launch and product approval.Q8. Which region will provide more business opportunities for the Hepatitis Testing/Diagnosis market during the forecast period?Ans. The Asia-Pacific region will provide more business opportunities for the Hepatitis Testing/Diagnosis market during the forecast period.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.